Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    In-Person

    A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline

    What is this Study about?

    The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.

    Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.

    Eligibility Criteria

    Male or female participants aged 55 to 80 years of age 
    Minimal to no cognitive/functional impairment at Screening
    Must have a study partner

    Recruitment End Date

    Find Out More